Tumor response predictors in radioimmunotherapy of previously untreated non-Hodgkin's lymphoma (NHL) with Iodine I 131 tositumomab.

被引：0
|
作者：
Zasadny, KR
Rommelfanger, SG
Regan, DD
McCullough, NT
Kroll, S
Stagg, R
Kaminski, MS
Wahl, RL
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Coulter Pharmaceut Inc, S San Francisco, CA USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2000年 / 41卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
114
引用
收藏
页码：29P / 30P
页数：2
相关论文
共 50 条
  • [31] 131I-tositumomab (Bexxar™) treatment does not preclude subsequent cytotoxic chemotherapy for non-Hodgkin's lymphoma (NHL).
    Dosik, A
    Kostakoglu, L
    Coleman, M
    Navarro, M
    Hack, S
    Fiore, JM
    Scarano, D
    Kroll, S
    Vallabhajosula, S
    Leonard, JP
    Goldsmith, SJ
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 116P - 116P
  • [32] Therapy Response Correlation with Tumor Radio-Sensitivity for Non-Hodgkin's Lymphoma Treated with 131I Tositumomab
    Roberson, P. L.
    Wilderman, S. J.
    Avram, A. M.
    Kaminski, M. S.
    Schipper, M. J.
    Dewaraja, Y. K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S336 - S336
  • [33] Results of a randomized study of Bexxar™ (tositumomab and iodine I 131 tositumomab) vs. unlabeled tositumomab in patients with relapsed or refractory low-grade or transformed non-Hodgkin's lymphoma (NHL).
    Davis, TA
    Kaminski, MS
    Leonard, JP
    Gregory, SA
    Wahl, R
    Hsu, FJ
    Wilkinson, M
    Frankel, SR
    Serafini, A
    Zelenetz, AD
    Kroll, S
    Coleman, M
    Levy, R
    Knox, SJ
    BLOOD, 2001, 98 (11) : 843A - 843A
  • [34] Bexxar, iodine I 131 tositumomab, effective in long term follow-up of non-Hodgkin's lymphoma
    Kaminski, Mark
    CANCER BIOLOGY & THERAPY, 2007, 6 (07) : 996 - 997
  • [35] Efficacy and safety of Bexxar® (tositumomab and iodine I 131 tositumomab) in obese patients with low-grade non-Hodgkin's lymphoma.
    Wahl, R
    Goldsmith, SJ
    Zasadny, KR
    Alavi, A
    Divgi, C
    Hankins, J
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 415P - 415P
  • [36] Pretargeted radioimmunotherapy (PRIT™) for treatment of non-Hodgkin's lymphoma (NHL)
    Weiden, PL
    Breitz, HB
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 40 (01) : 37 - 51
  • [37] Feasibility and safety of outpatient Bexxar® therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members
    Rutar, FJ
    Augustine, SC
    Kaminski, MS
    Wahl, RL
    Siegel, JA
    Colcher, D
    CLINICAL LYMPHOMA, 2001, 2 (03): : 164 - 172
  • [38] Tumor radiation dose and response to 131I tositumomab therapy for follicular lymphoma in previously-untreated
    Koral, KF
    Zasadny, KR
    Dewaraja, YK
    Li, J
    Regan, DD
    Rommelfanger, SG
    Francis, IR
    Kaminski, MS
    Wahl, RL
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 23P - 23P
  • [39] Treatment procedure for iodine-131Labeled antibody for Non-Hodgkin's lymphoma (NHL)
    Nair, M
    Anderson, P
    Neumann, T
    Mark, R
    MEDICAL PHYSICS, 2004, 31 (06) : 1925 - 1925
  • [40] Radioimmunotherapy with 131I-rituximab for patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL)
    Kang, Hye J.
    Lee, Seung S.
    Kim, Kyeong M.
    Choi, Tae H.
    Cheon, Gi J.
    Kim, Won S.
    Suh, Cheolwon
    Yang, Sung H.
    Lim, Sang M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2011, 7 (02) : 136 - +
12345